Drug intelligence / Profile preview

RWQWRWQWR-Ahx-KLALKLALK

Development stage: Preclinical
Lead developer: Universidad Nacional de Colombia
Modality: Peptides

Overview

RWQWRWQWR-Ahx-KLALKLALK is a synthetic hybrid peptide designed for the treatment of cervical cancer. It consists of a palindromic core sequence (RWQWRWQWR) derived from bovine lactoferricin (LfcinB) conjugated via a 6-aminohexanoic acid (Ahx) spacer to a cell-penetrating peptide (KLALKLALK). Developed by researchers in Colombia, the peptide exerts a rapid, concentration-dependent cytotoxic effect against cervical cancer cell lines such as HeLa and Ca Ski. Its mechanism of action involves initial electrostatic interactions between the positively charged arginine and lysine residues and the negatively charged components of the cancer cell surface, followed by membrane disruption or internalization to induce cell death.

Other names: RWQWRWQWR-Ahx-KLALKLALK

Beyond the preview

Go deeper on RWQWRWQWR-Ahx-KLALKLALK.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RWQWRWQWR-Ahx-KLALKLALK.

Explore the full profile